You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
ORAL PRESENTATIONS<br />
93<br />
Free Paper Session: Pressure Ulcers<br />
Exposures to Pressure injuries, a prospective cohorte study<br />
Anne-Birgitte Vogelsang 1<br />
1 Aarhus Universitetshospital (Aarhus, Denmark).<br />
Objective: To identify intrinsic and extrinsic exposures that increase the risk of patients<br />
developing a pressure injury (PI) during hospitalisation, and to estimate the relative risk<br />
(RR) associated with PI development.<br />
Method: Design: A prospective cohort study. Setting: an intensive care unit, a medical<br />
and a surgical unit. Observation period from the 28 March –11 April 2011, including 134<br />
patients.<br />
Outcome: PI prevalence and incidence. Exposures: Demographic, intrinsic and extrinsic<br />
risk factors. Statistics: were performed by Chi-squared test, Fischer’s exact test or<br />
Student’s t-test.<br />
Results: The incidence of PI was 26.7%, the prevalence of PI 2.2%, and overall<br />
occurrence of PI was 28.4%. The dichotomized exposures that increased the risk of<br />
having a PI was found to be, pressure on the same part of the body for more than 1½<br />
running hours during the past or next 24 hours RR 14.6 (2.08;102.9), limitation in activity<br />
performance the day after admission RR 12.6 (1.79;88.2), lack of willingness and/or<br />
ability to mobility RR 5.70 (1.86;17.6), systolic hypotension RR 3.88 (2.89;5.20),<br />
exposure to shear or friction when moved and/ or re-positioned and RR 3.80 (1.59;9.10),<br />
oedema RR 2.65 (1.60;4.38), sores or damaged skin 2.23 (1.33;3.73), skin exposed to<br />
moisture RR 2.16 (1.23;3.79), respiratory insufficiency or lung symptoms RR 2.17<br />
(1.27;3.69), partly conscious/unconscious RR 2.07 (1.22;3.53),<br />
Conclusion: The exposures that increased the risk of having a PI the most were all<br />
related to patient activity and mobility. The most important preventive step seems be<br />
insurance of changing position of the patient often enough.<br />
ETRS GUEST SESSION: WOUND HEALING AND WOUND RESEARCH<br />
94<br />
ETRS Guest Session: Wound Healing and Wound Research<br />
Cell therapy and tissue remodeling: fibroblast or fibroblast?<br />
Bernard Coulomb 1<br />
1 Institut national de la santé et de la recherche médicale, Centre de Recherche<br />
Cardiovasculaire (Paris, France)<br />
Tissue repair is a priority for any tissue or organ for recovering functional properties after<br />
injury. In contrast to embryo of several animal species in which the healing is perfect<br />
without any sequels, the wound healing in adults is generally associated with<br />
consequences (scar) that may lead to functional defects (e.g. hypertrophic scar in<br />
burns).<br />
In fact, efficiency of healing is depending on the tissue, and one can observe that<br />
gingival healing in adult can be considered as embryo-like. This is due to the ability of<br />
gingival fibroblasts to restore ad integrum the tissue without scar formation and fibrosis.<br />
We thus aimed to validate the concept of using gingival fibroblast healing properties in<br />
another tissue. The proof of this concept was first demonstrated in the context of arterial<br />
remodeling, both in vitro and in vivo in animal. This concept was also found valid to<br />
improve healing of irradiated burn lesions.<br />
As an example, in an experimental aneurysm model induced in rabbit carotid artery by<br />
elastase incubation, gingival fibroblasts cell therapy reduces the size of the aneurisms<br />
and restore the elastic network. In parallel, MMP-9 activity is decreased and TIMP-1<br />
secretion increased. Gingival fibroblasts persist at least three months within the arterial<br />
wall and are able to proliferate. None of these effects are obtained with dermal<br />
fibroblasts, illustrating the specific efficiency of gingival fibroblasts in tissue repair.<br />
This strategy is thus a promising approach to treat defects for which the current<br />
treatments do not treat the pathophysiology.<br />
66